Trial Profile
Phase 3 Trial, Randomized, Open-Label, of NOV-002 in Combination With Paclitaxel and Carboplatin vs. Paclitaxel and Carboplatin Alone for the Treatment of Advanced Non-Small-Cell Lung Cancer (NSCLC).
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 27 Jul 2022
Price :
$35
*
At a glance
- Drugs Glutathione/cisplatin (Primary) ; Glutathione/cisplatin (Primary) ; Carboplatin; Paclitaxel
- Indications Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Sponsors Cellectar Biosciences
- 11 Feb 2014 Novelos Therapeutics now known as Cellectar Biosciences
- 05 Jun 2010 Results presented as a late-breaking abstract at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO 2010).
- 06 Apr 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.